Top Technical Advances 2016

The year’s most impressive achievements include methods to watch translation in cells, trace cell fates, avoid mitochondrial mutations, edit DNA, and build antibiotics from scratch.

By | December 15, 2016

GEORGE RETSECKTranslation trackers

In quick succession this year, four independent teams came up with protocols for observing the birth of proteins as it happens. Three of the groups relied upon another newly developed tool, called SunTag, which fluorescently lights up proteins engineered to contain a particular epitope. The researchers combined SunTag with loops built into the proteins’ corresponding messenger RNAs, which are also fluorescently tagged. Rather than using SunTag, the fourth team engineered a different kind of epitope tag.

“The fact that you have four labs working on this is a testament to how hot the topic is,”  Colorado State University’s Tim Stasevich, whose lab developed one of the techniques, told The Scientist this year.

Nahum Sonenberg of McGill University in Canada who did not participate in the work said the four methods “provide insights and answers to questions that wouldn’t have been possible by biochemical means.”

                                                                                          JAMES GAGNONCell-lineage mappers

Numerous groups found ways to answer long-standing questions about the origins of various cell types, with equally varied approaches. One team adapted Brainbow—a transgenic approach originally devised for neural tissue—to monitor heart muscle cells in mice; another married the very precise isolation of a cell type with transcriptomics; and yet another deployed CRISPR-Cas9 with DNA barcodes to follow the fates of dividing cells in zebrafish.

Each of these techniques improves upon laborious, expensive, even previously impossible options for determining cell fate. On top of that, “none of [the previous iterations] work very well,” geneticist Aravinda Chakravarti of Johns Hopkins University School of Medicine told The Scientist this year.

GESTALT, the technique that inserts synthetic barcodes into a single fertilized zebrafish embryo and marks the barcodes with mutations, could be applied to studies of development, tumorigenesis, and tissue regeneration. “This method can be used to unravel any process that involves cell division,” said Chakravarti, who was not part of the project. “It’s a highly significant piece of work.”

WIKIMEDIA, PLOS ONEMitochondrial replacement therapy

Following on the heels of the birth of the first baby born by so-called three-parent in vitro fertilization, two papers published this year improve upon methods to fertilize embryos without bringing along damaging mutations from the mother’s mitochondrial DNA (mtDNA). A UK-based group used “pronuclear transfer,” which moves both sperm and pronuclei from a recently fertilized human egg into a nucleus-free donor bearing healthy mitochondria.

The concern has been that some unhealthy mitochondria tag along during the process, but the researchers were able to minimize their transfer. “The authors were able to optimize pronuclear transfer to a point where mitochondrial carryover was not a common problem,” stem cell researcher Paul Knoepfler at the University of California, Davis, told The Scientist this year. “The key open question is how little mitochondrial carryover is safe enough to proceed with this, clinically.”

Another method, called meiotic spindle transfer, moves nuclear DNA from the mother’s egg to an enucleated donor cell and then fertilizes it. “This is interesting work that nicely demonstrates effective replacement of mutant mtDNA in oocytes by spindle transfer, the feasibility of in vitro fertilization, and generation of healthy blastocytes and differentiated cells,” Michio Hirano, a professor of neurobiology at Columbia University in New York City who was not involved in the study wrote in an email to The Scientist this year.

WIKIMEDIA, TOM ELLENBERGER, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUISCRISPR with fewer cuts

As in the past few years since CRISPR’s debut as a genome-editing tool, this year saw a number of advances that have expanded its utility. In April, for instance, scientists reported on a derivation of CRISPR-Cas9 that replaces cytosine with uracil without cleaving both DNA strands, instead of using homology-directed repair to seal double-strand breaks in DNA. “By engineering this Cas9, they’ve figured out a really nice way to trick the cell into preferring pathways that it would normally not prefer,” Jacob Corn, the scientific director of the Innovative Genomics Initiative at the University of California, Berkeley, told The Scientist.

Following up in August, another group showed this approach could work using a different enzyme hitched to Cas9 (the nuclease that ordinarily cuts DNA) that also converts cytosine to uracil. This enzyme is called activation-induced cytidine deaminase (AID). “During double-stranded break repair, many things are going on at once and sometimes nucleotides are deleted and inserted or mutated in a way that is out of our control,” study coauthor Akihiko Kondo of Kobe University in Japan told The Scientist. Coauthor Keiji Nishida added: “The mutation rate [in the presence of AID] is acceptable, less than 10-fold higher compared to the natural background mutation rate.”

WIKIMEDIA, GIORGIOGP2Antibiotic building blocks

Researchers built more than 300 new antibiotics using a technique they developed using eight chemical building blocks. “It’s a tour de force in synthetic chemistry,” Kim Lewis of Northeastern University in Boston who was not involved in the study told The Scientist this year. “This is the first time there is a relatively easy path to synthesize macrolide erythromycin-type antibiotics from scratch.”

Typically, designing new antibiotics of this class require tweaking erythromycin, but such “semi-synthesis” would not be able to yield what the scientists could by starting from scratch.

Lab studies showed some of these compounds effectively killed bacteria, including some microbes resistant to existing antibiotics. “At the end of the day, it’s impossible to know whether or not they’re going to generate anything in clinic,” McMaster University’s Gerry Wright told The Scientist at the time. Still, “this is a significant step forward to regain the upper hand” against drug-resistant infections.

Thumbnail image: Flickr, Charles Clegg

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Streakers, Poopers, and Performers: The Wilder Side of Wildlife Cameras
AAAS